E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

Research output: Contribution to journalArticle

109 Citations (Scopus)
Original languageEnglish
Pages (from-to)421-422
Number of pages2
JournalClinical Breast Cancer
Volume3
Issue number6
StatePublished - 2003

Fingerprint

Paclitaxel
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Clinical Trials
Breast Neoplasms
Drug Therapy
Bevacizumab

Keywords

  • Angiogenesis
  • Chemotherapy
  • Clinical trial
  • Monoclonal antibody
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research

Cite this

E2100 : A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. / Miller, Kathy.

In: Clinical Breast Cancer, Vol. 3, No. 6, 2003, p. 421-422.

Research output: Contribution to journalArticle

@article{0db3dca30f5f4385aa44563675b5858c,
title = "E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer",
keywords = "Angiogenesis, Chemotherapy, Clinical trial, Monoclonal antibody, Vascular endothelial growth factor",
author = "Kathy Miller",
year = "2003",
language = "English",
volume = "3",
pages = "421--422",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - E2100

T2 - A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

AU - Miller, Kathy

PY - 2003

Y1 - 2003

KW - Angiogenesis

KW - Chemotherapy

KW - Clinical trial

KW - Monoclonal antibody

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0037303885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037303885&partnerID=8YFLogxK

M3 - Article

C2 - 12636887

AN - SCOPUS:0037303885

VL - 3

SP - 421

EP - 422

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -